Prescription patterns of ambrisentan in some cities of Colombia

Clin Respir J. 2024 Mar;18(3):e13736. doi: 10.1111/crj.13736.


Introduction: Ambrisentan is a selective type A endothelin receptor antagonist that has shown significant effectiveness and safety in the management of patients with pulmonary hypertension. Its use pattern with real-world evidence in Colombia is unknown.

Objective: The objective of this study is to determine the prescription patterns of ambrisentan in some cities of Colombia.

Methods: A longitudinal descriptive study on the prescription patterns of ambrisentan in patients with pulmonary hypertension (all the groups) was conducted between January 2021 and December 2022 based on a population database of members of the Colombian Health System. Adherence at 1 year was determined using the Medication Possession Ratio (days the drug was dispensed/days from first dispensing to the end of the follow-up period × 100). Descriptive analysis was carried out.

Results: Sixty-seven patients taking ambrisentan were identified in 10 cities of the country. The individuals had a median age of 51.5 years (interquartile range-IQR: 39.8-64.0 years), and 82.1% were women. The drug possession rate was 82.2% (IQR: 65.0-96.8%), and persistence at 1 year was present in 49.3% (n = 33) of the cases. The average dose was 8.8 ± 5.0 mg/day, and 76.1% (n = 51) received it in combination therapy, mainly with phosphodiesterase type 5 inhibitors (61.2%, n = 41).

Conclusions: Adherence to ambrisentan was good, but its persistence at 1 year was low. The dosages of the drug used were in accordance with the recommendations of the clinical practice guidelines, and it was used in combination therapy, especially with phosphodiesterase 5 inhibitors.

Keywords: Colombia; ambrisentan; hypertension; medication adherence; pharmacoepidemiology; pulmonary.

MeSH terms

  • Adult
  • Cities
  • Colombia / epidemiology
  • Female
  • Humans
  • Hypertension, Pulmonary*
  • Male
  • Middle Aged
  • Phenylpropionates*
  • Pyridazines*
  • Treatment Outcome


  • ambrisentan
  • Phenylpropionates
  • Pyridazines

Grants and funding